PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice

Mulu Z. Tesfay, Amber C. Kirk, Elizabeth M. Hadac, Guy E. Griesmann, Mark J. Federspiel, Glen N Barber, Stephen M. Henry, Kah Whye Peng, Stephen J. Russell

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of multiple myeloma, an incurable malignancy of antibody-secreting plasma cells that are specifically localized in the bone marrow. One of the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and preexisting anti-VSV immunity is typically lacking in cancer patients, which is very important for clinical success. However, our studies show that nonimmune human and mouse serum can neutralize clinical-grade VSV, reducing the titer by up to 4 log units in 60 min. In addition, we show that neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV administration. We have investigated the potential use of covalent modification of VSV with polyethylene glycol (PEG) or a function-spacer-lipid (FSL)-PEG construct to inhibit serum neutralization and to limit hepatosplenic sequestration of systemically delivered VSV. We report that in mice passively immunized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the blood circulation, maintaining a more than 1-log-unit increase in VSV genome copies for up to 1 h compared to the genome copy numbers for the non-PEGylated virus, which was mostly cleared within 10 min after intravenous injection. We are currently investigating if this increase in PEGylated VSV circulating half-life can translate to increased virus delivery and better efficacy in mouse models of multiple myeloma.

Original languageEnglish
Pages (from-to)3752-3759
Number of pages8
JournalJournal of Virology
Volume87
Issue number7
DOIs
StatePublished - Apr 1 2013

Fingerprint

Vesiculovirus
blood circulation
Vesicular Stomatitis
Blood Circulation
Viruses
viruses
mice
neutralization
myeloma
polyethylene glycol
Multiple Myeloma
antibodies
Oncolytic Viruses
Genome
Antibody-Producing Cells
genome
plasma cells
Antibodies
intravenous injection
Plasma Cells

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Tesfay, M. Z., Kirk, A. C., Hadac, E. M., Griesmann, G. E., Federspiel, M. J., Barber, G. N., ... Russell, S. J. (2013). PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. Journal of Virology, 87(7), 3752-3759. https://doi.org/10.1128/JVI.02832-12

PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. / Tesfay, Mulu Z.; Kirk, Amber C.; Hadac, Elizabeth M.; Griesmann, Guy E.; Federspiel, Mark J.; Barber, Glen N; Henry, Stephen M.; Peng, Kah Whye; Russell, Stephen J.

In: Journal of Virology, Vol. 87, No. 7, 01.04.2013, p. 3752-3759.

Research output: Contribution to journalArticle

Tesfay, MZ, Kirk, AC, Hadac, EM, Griesmann, GE, Federspiel, MJ, Barber, GN, Henry, SM, Peng, KW & Russell, SJ 2013, 'PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice', Journal of Virology, vol. 87, no. 7, pp. 3752-3759. https://doi.org/10.1128/JVI.02832-12
Tesfay, Mulu Z. ; Kirk, Amber C. ; Hadac, Elizabeth M. ; Griesmann, Guy E. ; Federspiel, Mark J. ; Barber, Glen N ; Henry, Stephen M. ; Peng, Kah Whye ; Russell, Stephen J. / PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. In: Journal of Virology. 2013 ; Vol. 87, No. 7. pp. 3752-3759.
@article{e879a034100c411981b9df988d82a097,
title = "PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice",
abstract = "We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of multiple myeloma, an incurable malignancy of antibody-secreting plasma cells that are specifically localized in the bone marrow. One of the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and preexisting anti-VSV immunity is typically lacking in cancer patients, which is very important for clinical success. However, our studies show that nonimmune human and mouse serum can neutralize clinical-grade VSV, reducing the titer by up to 4 log units in 60 min. In addition, we show that neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV administration. We have investigated the potential use of covalent modification of VSV with polyethylene glycol (PEG) or a function-spacer-lipid (FSL)-PEG construct to inhibit serum neutralization and to limit hepatosplenic sequestration of systemically delivered VSV. We report that in mice passively immunized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the blood circulation, maintaining a more than 1-log-unit increase in VSV genome copies for up to 1 h compared to the genome copy numbers for the non-PEGylated virus, which was mostly cleared within 10 min after intravenous injection. We are currently investigating if this increase in PEGylated VSV circulating half-life can translate to increased virus delivery and better efficacy in mouse models of multiple myeloma.",
author = "Tesfay, {Mulu Z.} and Kirk, {Amber C.} and Hadac, {Elizabeth M.} and Griesmann, {Guy E.} and Federspiel, {Mark J.} and Barber, {Glen N} and Henry, {Stephen M.} and Peng, {Kah Whye} and Russell, {Stephen J.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1128/JVI.02832-12",
language = "English",
volume = "87",
pages = "3752--3759",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice

AU - Tesfay, Mulu Z.

AU - Kirk, Amber C.

AU - Hadac, Elizabeth M.

AU - Griesmann, Guy E.

AU - Federspiel, Mark J.

AU - Barber, Glen N

AU - Henry, Stephen M.

AU - Peng, Kah Whye

AU - Russell, Stephen J.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of multiple myeloma, an incurable malignancy of antibody-secreting plasma cells that are specifically localized in the bone marrow. One of the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and preexisting anti-VSV immunity is typically lacking in cancer patients, which is very important for clinical success. However, our studies show that nonimmune human and mouse serum can neutralize clinical-grade VSV, reducing the titer by up to 4 log units in 60 min. In addition, we show that neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV administration. We have investigated the potential use of covalent modification of VSV with polyethylene glycol (PEG) or a function-spacer-lipid (FSL)-PEG construct to inhibit serum neutralization and to limit hepatosplenic sequestration of systemically delivered VSV. We report that in mice passively immunized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the blood circulation, maintaining a more than 1-log-unit increase in VSV genome copies for up to 1 h compared to the genome copy numbers for the non-PEGylated virus, which was mostly cleared within 10 min after intravenous injection. We are currently investigating if this increase in PEGylated VSV circulating half-life can translate to increased virus delivery and better efficacy in mouse models of multiple myeloma.

AB - We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatment of multiple myeloma, an incurable malignancy of antibody-secreting plasma cells that are specifically localized in the bone marrow. One of the presumed advantages for using VSV as an oncolytic virus is that human infections are rare and preexisting anti-VSV immunity is typically lacking in cancer patients, which is very important for clinical success. However, our studies show that nonimmune human and mouse serum can neutralize clinical-grade VSV, reducing the titer by up to 4 log units in 60 min. In addition, we show that neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV administration. We have investigated the potential use of covalent modification of VSV with polyethylene glycol (PEG) or a function-spacer-lipid (FSL)-PEG construct to inhibit serum neutralization and to limit hepatosplenic sequestration of systemically delivered VSV. We report that in mice passively immunized with neutralizing anti-VSV antibodies, PEGylation of VSV improved the persistence of VSV in the blood circulation, maintaining a more than 1-log-unit increase in VSV genome copies for up to 1 h compared to the genome copy numbers for the non-PEGylated virus, which was mostly cleared within 10 min after intravenous injection. We are currently investigating if this increase in PEGylated VSV circulating half-life can translate to increased virus delivery and better efficacy in mouse models of multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84875541589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875541589&partnerID=8YFLogxK

U2 - 10.1128/JVI.02832-12

DO - 10.1128/JVI.02832-12

M3 - Article

C2 - 23325695

AN - SCOPUS:84875541589

VL - 87

SP - 3752

EP - 3759

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 7

ER -